How Wegovy programs are structured for weight loss in the UK

The trial foundation: what STEP 1 actually tested

The STEP 1 trial enrolled 1,961 adults with obesity or overweight and at least one weight-related condition, without type 2 diabetes. Participants received either semaglutide 2.4mg weekly or placebo, both alongside structured lifestyle intervention, a calorie-reduced diet and increased activity targets. At 68 weeks, the semaglutide group had lost roughly 15% of starting body weight on average, compared with around 2.4% in the placebo group.

That gap tells you something important about how Wegovy programs are designed. The lifestyle component was not optional decoration; it was a core part of the protocol, and both groups received it. The medicine's effect is measured on top of that foundation. Any structured program that reflects the evidence will treat diet and activity support as integral, not bolt-on extras.

The NICE appraisal of semaglutide (NICE TA875) reinforces this: its recommendation for NHS use requires semaglutide to be delivered within a specialist weight management service with multidisciplinary support, for a maximum of two years. That framing came directly from how the trial was conducted.

How the dose schedule shapes the experience of a Wegovy program

A Wegovy program is not a single dose repeated indefinitely. The licensed escalation pathway starts at 0.25mg weekly and moves through 0.5mg, 1.0mg, 1.7mg and 2.4mg, with roughly four weeks at each level. The pace is set by the prescriber based on tolerance, not by a fixed calendar.

This matters practically. Most people notice gastrointestinal side effects (nausea, changes to appetite, sometimes loose stools) most acutely when the dose increases. Titrating slowly gives the body time to adjust. The 0.25mg starting dose is not intended to produce significant weight loss on its own; its job is to settle the system before the therapeutic doses begin. The NHS semaglutide medicines page covers the common side effects and what to expect during this adjustment period.

In January 2026 the MHRA approved a higher 7.2mg maintenance dose for Wegovy, with a dedicated single-dose pen approved in April 2026 for adults with a BMI of 30 or above. Trial data for 7.2mg reported average weight loss of around 20.7% over 72 weeks, approaching the results seen with tirzepatide at its highest dose. Specific dose availability is confirmed during a clinical consultation rather than assumed in advance. If you want a broader picture of how the full semaglutide dose range is structured, our page on Wegovy milligrams covers each strength in detail.

NHS programs versus private programs: what differs in practice

On the NHS, a Wegovy program is delivered through a specialist weight management service, as NICE TA875 specifies. Access is phased and criteria are strict, typically requiring a BMI of 35 or above plus at least one weight-related comorbidity, and a referral through your GP. Waiting lists in many areas are long.

Private programs follow the same clinical evidence base (the same medicine, the same dose schedule, the same licensed indications) but the access route is different. A GPhC-registered online pharmacy conducts a clinical consultation, a qualified prescriber reviews the answers personally, and if treatment is appropriate it can be dispatched the same day. There is no referral, no waiting list.

What varies between private providers is what surrounds the prescription: whether repeat supplies include a clinical re-review, whether aftercare support is available between doses, and how transparent the pricing is. Our Wegovy weight loss program page explains how the ongoing care model works in practice. If you are comparing what different programs cost and what those prices typically include, the weight loss treatments overview gives a grounded picture of the private market.

What arriving on a Wegovy program actually looks like

For people who have only seen Wegovy described in abstract terms, the physical reality is straightforward. The medicine comes as a pre-filled pen; you inject once a week, rotating between the abdomen, thigh and upper arm. When ordered through a regulated UK pharmacy, the pen arrives in plain, unbranded packaging via DPD tracked delivery, you can follow it on your phone and it reaches you the next working day if the order is placed before noon and approved the same day.

Before a prescriber approves any supply, they review a clinical consultation, verify your identity and weight, and check the information you have provided against the eligibility criteria. For transfers from another provider or dose increases, evidence is required. That review happens before every repeat, not just at the start. If cost is a consideration, our page on the Wegovy assistance program sets out the support options that may be available to help with pricing. Our semaglutide overview covers the pharmacology and mechanism in more depth, and the Wegovy pillar page brings together the full range of topics around this treatment.

If you have questions before starting, the FAQs address the most common ones, or you can reach the clinical team through the contact page. To understand the eligibility criteria your prescriber will work through, our clinical team page explains who conducts the reviews and how the process is governed. For a realistic sense of what results can look like over time, our collection of Wegovy progress pics shows how different people have responded at various stages of treatment.